Abstract:HASPIN, a mitotic kinase to phosphorylate Histone H3 at centromere, has been studied as a promising target for anti-cancer therapy. However, as HASPIN belongs to atypical kinase, lacking the Asp-Phe-Gly (DFG) motif, development from the chemical library of kinase inhibitors with conventional pharmacophore, would be technically challenging. In particular, one of adenosine analogues (LJ4827), a potent inhibitor of multi-kinases, showing clear anti-cancer activity in vitro and in vivo, was predicted as a HASPIN inhibitor by computation analysis of its transcriptome profile in cancer cells to drug-omic data set in the connectivity MAP (cMAP) as it shared similar transcriptome profile of 5-iodotubercidin (5ITU). The specificity and potency as HASPIN inhibitor of LJ4827 (IC50 = 0.45 nM) validated by in vitro kinase screening and consequent 3D structure modeling. As expected, treatment of LJ4827 in cancer cell lines efficiently delayed mitotic progression without double strand break (DSB) unlike 5ITU and significantly attenuated Aurora B localization at centromere. Along with clinical significance of HASPIN expression in lung cancer patients, mitotic gene signature closely associated to high expression of HASPIN, revealed the poor prognosis. Additional computational analysis of kinase perturbation data to predict the dependency of mitotic kinase in the absence of HASPIN activity, revealed the synthetic lethal effect of cotreatment of the chemical inhibitor of BUB1, PLK1 or AURKA with LJ4827. These data suggest that combined inhibition of HASPIN with the novel inhibitor and key mitotic kinases for centromere/kinetochore regulation would be effectivity therapeutic approach for cancer therapy. Citation Format: Eun-Ji Kwon, Karishma Mashelkar, Hyuk Woo Lee, Yoon-Ze Shin, Lak Shin Jeong, Hyuk-Jin Cha. Identification of a novel HASPIN inhibitor and the synthetic lethal partner by computational analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3949.

Synthesis and evaluation of novel N1-acylated 5-(4-pyridinyl)indazole derivatives as potent and selective haspin inhibitors

N1‐Benzoylated 5‐(4‐pyridinyl)indazole‐based kinase inhibitors: Attaining haspin and Clk4 selectivity via modulation of the benzoyl substituents

A Comprehensive In Vitro Characterization of a New Class of Indole-Based Compounds Developed as Selective Haspin Inhibitors

Synthesis and biological evaluation of 1H-pyrrolo[3,2–g]isoquinolines

Discovery of a New Dihydropyrimidinone Derivative as a Potential Haspin Kinase Inhibitor: Structure‐Guided Insights, In‐Vitro and Molecular Dynamics‐Based Validation

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Identification of indole-grafted pyrazolopyrimidine and pyrazolopyridine derivatives as new anti-cancer agents: Synthesis, biological assessments, and molecular modeling insights

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Abstract 3949: Identification of a novel HASPIN inhibitor and the synthetic lethal partner by computational analysis

Thieno[3,2‐b]pyridine: Attractive scaffold for highly selective inhibitors of underexplored protein kinases with variable binding mode

Design and Synthesis of Indole Pyrimidine Scaffolds as Potential KSP Inhibitors and Anticancer Agents

Synthesis and HDAC1 inhibitory activity of a novel series of coumarin-based amide derivatives for treatment of cancer

Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer

Combined computational and synthetic strategies for the development of potent pyrazolo-pyridine derivatives as anticancer agents

Homology modelling, molecular docking studies and synthesis of aminopyrimidines as inhibitors for deoxynucleoside kinase analogues in cancer chemoprevention

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors

Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors

Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.